| Market Cap | 4.16M | P/E | - | EPS this Y | - | Ern Qtrly Grth | 483.10% |
| Income | -218.47k | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -7.00% |
| Sales | 2.67M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -18.00% |
| Dividend | N/A | Price/Book | 3.13 | EPS next 5Y | - | 52W High Chg | -53.00% |
| Recommedations | - | Quick Ratio | 0.66 | Shares Outstanding | - | 52W Low Chg | 7.00% |
| Insider Own | - | ROA | -9.25% | Shares Float | - | Beta | -1.51 |
| Inst Own | - | ROE | -31.64% | Shares Shorted/Prior | -/- | Price | 0.08 |
| Gross Margin | 76.19% | Profit Margin | -8.18% | Avg. Volume | 5,875 | Target Price | - |
| Oper. Margin | 11.26% | Earnings Date | - | Volume | 13,800 | Change | 0.00% |
Kelyniam Global, Inc., a medical device manufacturing company, engages in the production of custom prosthetics cranial implants utilizing computer aided design, and computer aided manufacturing of advanced medical grade polymers in the United States. The company is also involved in the development, manufacture, and distribution of custom cranial and maxilla-facial implant for patients requiring the reconstruction of cranial and facial structures. It serves surgeons, health systems, and payors. The company was formerly known as Ketner Global Investments, Inc. and changed its name to Kelyniam Global, Inc. in December 2007. Kelyniam Global, Inc. was incorporated in 2005 and is based in Collinsville, Connecticut.
